Emerging treatments for viral retinitis

BioDrugs

Volumn 7, Issue 6, 1997, Pages 423-432

  Nokta, Mostafa A ^a   Hausrath, Stephen G ^a   Pollard, Richard B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR;

CYTOMEGALOVIRUS; DISEASE COURSE; DRUG EFFICACY; EMERGENCY TREATMENT; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE DEFICIENCY; INTRAOCULAR DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; REVIEW; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 0030756055     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707060-00001     Document Type: Review

References (103)

1. Duker JS, Blumenkranz MS. Diagnosis and management of the acute retinal necrosis (ARN) syndrome. Surv Ophthalmol 1991; 35: 327
2. Culbertson WW. Acute retinal necrosis and similar retinitis syndromes. In: Smolin G, Friedlander MH, editors. New and evolving ocular infections. Int Ophthalmol Clinics, Boston: Little Brown, 1993
3. de la Paz M, Young LHY. Acute retinal necrosis syndrome. Semin Ophthalmol 1993; 8: 61
4. Hagler WS, Walters PV, Nahmias AL. Ocular involvement in neonatal herpes simplex virus infection. Arch Ophthalmol 1969; 82: 169-76
5. Johnson BL, Wisotzkey HM. Neuroretinitis associated with herpes simplex encephalitis in an adult. Am J Ophthalmol 1977; 83: 481-9
6. Minckler DS, McLean EB, Shaw CM, et al. Herpesvirus hominis encephalitis and retinitis. Arch Ophthalmol 1976; 94: 89-95
7. Partamian LG, Morse PH, Klein HZ. Herpes simplex type 1 retinitis in an adult with systemic herpes zoster. Am J Ophthalmol 1981; 92: 215-20
8. Selby PJ, Powles RL, Janeson B, et al. Parenteral acyclovir therapy for herpes virus infections in man. Lancet 1979; 11: 1267-70
9. Straus SE, Smith HA, Brickman C, et al. Acyclovir for chronic mucocutaneous herpes simplex virus injection in immunosuppressed patients. Ann Intern Med 1982; 96: 270-7
10. Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982; 96: 265-9
11. Hellinger WC, Bolling JP, Smith TF, et al. Varicella-zoster virus retinitis in a patient with AIDS-related complex: case report and brief review of the acute retinal necrosis syndrome. Clin Infect Dis 1993 Feb; 16(2): 208-12
12. Culbertson WW. Viral retinitis. In: Tabarra KF, Hyndiuk RA, editors. Infections of the eye. New York: Little Brown Company, 1996: 499-510
13. Forster DJ, et al. Rapidly progressive outer retinal necrosis in the acquired immunodeficiency syndrome. Am J Ophthalmol 1990; 110: 341
14. Pavan-Langston D. Major ocular viral infections. In: Galasso GJ, Whitley RJ, Merigan TC, editors. Antiviral agents and viral diseases of man. 3rd ed. New York: Raven Press, 1990: 183-227
15. Gretch DR, Kari B, Rasmussen L, et al. Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. J Virol 1988; 62: 875-81
16. Britt WJ, Vugler L, Butifiloski EJ, et al. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990; 64: 1079-85
17. Liu Y-NC, Kari B, Gehrz C. Human immune responses to major human cytomegalovirus glycoprotein complexes. J Virol 1988; 62: 1066-70
18. Rasmussen L, Matkin C, Spaete R, et al. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 1991; 164: 835-42
19. Rasmussen L. Immune response to human cytomegalovirus infection. Curr Top Microbiol Immunol 1990; 154: 221-54
20. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990 Sep-Oct; 12 Suppl. 7: S701-10
21. Stagno S, Pass RF, Dworsky ME, et al. Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol 1982; 25: 563-76
22. Gurevich I, Cunha BA. Non-parenteral transmission of cytomegalovirus in a neonatal intensive care unit. Lancet 1981; 11: 222-4
23. Pass RF, Hutto C. Group day care and cytomegalovirus infections of mothers and children. Rev Infect Dis 1986; 8: 599-605
24. Chretien JH, McGinniss CG, Muller A. Venereal causes of cytomegalovirus mononucleosis. JAMA 1977; 238: 1644-5
25. Jordan MC, Rousseau WE, Noble GR, et al. Association of cervical cytomegaloviruses with venereal disease. N Engl J Med 1973; 288: 932-4
26. Willmott FE. Cytomegalovirus in female patients attending a VD clinic. Br J Vener Dis 1975; 51: 278-80
27. Chandler SH, Holmes KK, Wentworth BB, et al. The epidemiology of cytomegaloviral infection in women attending a sexually transmitted disease clinic. J Infect Dis 1985; 152: 597-605
28. Handsfield HH, Chandler SH, Caine VA, et al. Cytomegalovirus infection in sex partners: evidence for sexual transmission. J Infect Dis 1985; 151: 344-8
29. Drew WL, Mintz L, Miner RC, et al. Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981; 143: 188-92
30. Greenberg SB, Linder S, Baxter B, et al. Lymphocyte subsets and urinary excretion of cytomegalovirus among homosexual men attending a clinic for sexually transmitted diseases. J Infect Dis 1984; 150: 330-3
31. Doldi K, Leroux M, Kirchner H, et al. Proliferative responses to human cytomegalovirus in lymphocyte cultures of male homosexuals. J Clin Lab Immunol 1985; 17: 111-4
32. Coutinbo RA, Wertheim-Van Dillen P, Albrecht-Van Lent P, et al. Infection with cytomegalovirus in homosexual men. Br J Vener Dis 1984; 60: 249-52
33. Mintz L, Drew WL, Miner RC, et al. Cytomegalovirus infections in homosexual men: an epidemiological study. Ann Intern Med 1983; 99: 326-9
34. Collier AC, Meyers JD, Corey L, et al. Cytomegalovirus infection in homosexual men: relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med 1987; 82: 593-600
35. Ho M. Cytomegalovirus: biology and infection. New York: Plenum, 1991
36. Kaariainen L, Klemola E, Paloheimo J. Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. BMJ 1996; 1: 1270-2
37. Stover DE, White DA, Romano PA, et al. Spectrum of pulmonary disease associated with the acquired immunodeficiency syndrome. Am J Med 1985; 78: 429-37
38. Wallace JM, Hannah J. Cytomegalovirus pneumonitis in patients with AIDS. Chest 1985; 92 (12): 198-203
39. Quinnan Jr GV, Masur H, Rook AH, et al. Herpes virus infections in the acquired immunodeficiency syndrome. JAMA 1984; 52: 72-6
40. Schooley RT. Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis 1990; 12: 5811-9
41. Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the opthalmologic findings in the acquired immune deficiency syndrome. Am J Pathol 1984; 97: 133-42
42. Palestine AG, Rodrigues MM, Macher AM, et al. Opthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984; 91: 1092-9
43. Shinkai M, Spector SA. Quantitation of human CMV DNA in plasma and cerebrospinal fluid (CSF) by competitive PCR identifies AIDS patients at highest risk for CMV diseases [abstract 14]. Fifth International Cytomegalovirus Conference: 1995 May; Stockholm, Sweden, 1995: 67
44. Buhles WC, Jr Mastre BJ, Tinker AJ, et al. The Syntex Collaborative Ganciclovir Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988; 10: S495-506
45. Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-(2-hydroxy-1-(hydroxymethyl)ethoxymethyl)guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 19885; 103: 368-73
46. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infection with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986; 314: 801-5
47. Ringden O, Lonnqvist B, Paulin T, et al. Pharmacokinetics, safety and preliminary clinical experience using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986; 17: 373-87
48. Singer DRJ, Fallon TJ, Schulenburg WE et al. Foscarnet for cytomegalovirus retinitis. Ann Intern Med 1985; 103: 962
49. Walmsley LL, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 1988; 157: 569-72
50. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995 Apr; 171 (4): 788-96
51. Kirsch LS, Arevalo JF, DeClercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995 Apr; 119 (4): 466-76
52. Polis MA, Spooner KM, Baird BF, et al. Anti-cytomegaloviral activity and safely of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995 Apr; 39 (4): 882-6
53. Felsenstein D, Dimico D, Hirsch N, et al. Treatment of cytomegalovirus retinitis with 9-(2-hydroxy-1-(hydroxymethyl)propoxymethyl)guanine. Ann Intern Med 1985; 103: 377-80
54. Erice A, Jordan C, Chace B, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987; 257: 3082-7
55. Youle MS, Clarbour J, Gazzard B, et al. Severe hypocalcaemia in AIDS patients treated with PFA and pentamidine. Lancet 1988; 1: 1455-6
56. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995 Apr; 39 (4): 882-6
57. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358: 160-2
58. Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358: 162-4
59. Chrisp P, Clissold SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: 104-29
60. Neyts J, De Clercq E. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. Biochem Pharmacol 1994 Jan; 47 (1): 39-41
61. Ho HT, Woods KL, Bronson JJ, et al. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydioxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol Jan; 41 (1): 197-202
62. Erice A, Chou S, Biron KK, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289-93
63. Mahalko S, Gordon M, Owen WF, et al. Prevalence of CMV resistant in patients receiving ganciclovir for serious CMV infection. J Infect Dis 1991; 163: 716-9
64. Lurain NS, Thompson KD, Holmes EW, et al. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistane to antiviral agents. J Virol 1992 Dec; 66 (12): 7146-52
65. Sullivan V, Biron KK, Talarico C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993 Jan; 37 (1): 19-25
66. Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994 Jul; 68 (7): 4427-31
67. Wolf DG, Smith IL, Lee DJ, et al. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 1995 Jan; 95 (1): 257-63
68. Chou S, Guentzel S, Michele KR, et al. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995 Jul; 172 (1): 239-42
69. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995 Mar; 171 (3): 576-83
70. Sarasini A, Baldanti F, Furione M, et al. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J Med Virol 1995 Nov; 47 (3): 237-44
71. Polis MA. Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1992; 1 Suppl. 5: S3-10
72. Cherrington MS, Smith IL, Jiles RE, et al. Ganciclovir resistant CMV: implications of UL97 and polymerase mutations in cross resistance to cidofovir [abstract]. XI International Conference on Antiviral Research: 1996 May; Urabandai, Fukushima, Japan: 19-24
73. Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991 163: 1348-51
74. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. J Med 1992 Jan 23; 326 (4): 213-20
75. Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993 168: 444-8
76. Feinberg J, Squires K. Treatment and prevention of CMV disease. Improv Manage HIV Dis 1995; 4: 4-7
77. Azad RF, Driver VB, Tanaka K, et al. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993 Sep; 37 (9): 1945-54
78. Azad RF, Brown-Driver V, Buckheit Jr RW, et al. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res 1995 Oct; 28 (2): 101-11
79. Henry K, Cantrill HL, Fletcher C, et al. Use of intravitreal ganciclovir(dihydroxypropoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103: 17-23
80. Ussery FM III, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1989; 95: 640-8
81. Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long term results. Ophthalmology 1989; 96: 367-74
82. Heinemann M-H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989; 107: 1767-72
83. Cochereau-Massin I, LeHoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991; 98: 1348-53
84. Kirsch LS, Arevalo JF, Chavez de al Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995 May; 102 (4): 533-42
85. Kirsch LS, Arevalo JF, Chavez de al Paz E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995 Apr; 199 (4): 466-76
86. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 1994 Dec; 112: 1531-9
87. Nelson MR, Barter G, Hawkins D, et al. Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Lancet 1991 Jul 27; 338: 250
88. Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1993; 167: 1184-8
89. Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS Arch Ophthalmol 1996 Jan; 144: 23-33
90. Drew WL. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. J Acquir Immune Defic Syndr 1991; 4 Suppl. 1: S42-6
91. Erice A, Chou S, Biron KK, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320: 289-93
92. Snydman DR, Werner BG, Tilney NL, et al. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant Proc 1988; 8 (20 Suppl.): 24-30
93. Reed EC, Bowden RA, Dandliker PS, et al. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 1987; 156: 641-5
94. Reed EC, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987; 257: 3082-7
95. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777-82
96. Bratanow NC, Ash RC, Turner PA, et al. Successful treatment of serious cytomegalovirus (CMV) disease with 9-(1,3-dihydioxy-2-propoxymethl)guanine (ganciclovir, DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients [abstract 254]. Exp Hematol 1987; 15: 541
97. Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988; 46: 905-7
98. Verdonck LF, de Gast DC, Dekker A, et al. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 1989; 4: 187-9
99. Lakeman F, Blevins BS, Whitley R, et al. In vitro neutralization of cytomegalovirus (CMV) strains by a human monoclonal antibody, MSL-109. Antiviral Res 1991; 15 Suppl. 1: 77
100. Nokta M, Tolpin MD, Nadler PI, et al. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res 1994; 24: 17-26
101. Aulitzky WE, Schulz TF, Tilg H, et al. Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. J Infect Dis 1991; 163: 1344-7
102. Drobyski WR, Gottlieb M, Carrigan D, et al. Phase I study of safety and pharmacokinetics of a human anti-cytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 1991 Jun; 51 (6): 1190-6
103. Tolpin M, Pollard R, Tierney M, et al. Combination therapy of cytomegalovirus (CMV) retinitis with a human monoclonal anti-CMV antibody (SDZ MSL 109) and either ganciclovir (DHPG) or foscarnet (PFA) [abstract]. IX International Conference on AIDS: 1993 Jun 7-11; Berlin, Germany